Quentis Therapeutics, Inc

📍 New York, United States🗓 Founded 2016👥 6 employees💰 Last funded Feb 2018
🌐 quentistx.com
Website LinkedIn
The endoplasmic reticulum is a structure within cells that is responsible for multiple functions, including serving as a sensor of cellular stress. Persistent ER stress has a significant impact in a number of diseases including cancer and neurodegenerative disease, as well as autoimmune conditions. Quentis Therapeutics is translating novel biology into new therapeutic approaches to address ER stress in multiple diseases, beginning with our first program in cancer. The company’s first-in-class IRE1α inhibitor is designed to target ER stress pathways and awaken the immune system’s ability to fight cancer. Founded by a team with deep drug discovery and development experience, we are building a leading New York City-based biotechnology company driven by a commitment to scientific excellence and a passion to help patients.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Quentis Therapeutics, Inc?
Quentis Therapeutics, Inc has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Quentis Therapeutics, Inc last raise funding?
The most recent investment in Quentis Therapeutics, Inc recorded on gritt.io was in February 2018.
When was Quentis Therapeutics, Inc founded?
Quentis Therapeutics, Inc was founded in 2016.
Where is Quentis Therapeutics, Inc based?
Quentis Therapeutics, Inc is headquartered in New York, United States.